A Sign of Cancer in Blood Tests: Tumor DNA Fragments (ctDNA). Series-3

Cancer can be treated if diagnosed early. However, a lack of biomarkers that enable early cancer diagnosis leads to diagnosis at a late stage. In recent years, researchers have focused primarily on discovering biological molecules that can reveal cancer through a simple blood test, also called a liquid biopsy. Promising developments in this area are coming from genetics.
Researchers began detecting genetic changes (mutations) that cause uncontrolled cell division, succeeding in mapping the cancer cell's genetic makeup. All these studies found that most cancer cells carry somatic DNA mutations . Somatic mutations are damage occurring in an individual's genetic makeup and are not inherited by offspring. They persist until the person dies. Because this type of mutation is found only in cancer cells, it is considered a promising biomarker for detecting and monitoring cancer cells.
Recent studies discovered that dying cancer cells release DNA fragments into the blood. These DNA fragments are called circulating tumor DNA fragments (circulating tumor DNA = ctDNA) . Research completed in 2014 identified a potential role for tumor DNA fragments in detecting these mutations and monitoring tumor progression. Circulating tumor DNA fragments were first discovered in urine. Many biotechnology companies have designed tests and made them available to physicians. The first is a test developed by Trovagene using a blood or urine sample. It seeks to detect mutations in BRAF V600E and KRAS proteins, which are frequently seen in cancer cells.
A study published in Science Translational Medicine in 2014, involving 17 different cancer types and 187 patients, detected mutations in circulating tumor cells in 82 percent of patients other than those with brain cancer. Detectable ctDNA mutations were also reported in 55 percent of patients with early-stage cancer. One of the researchers' most important observations was that the number of circulating tumor DNA fragments increases as the cancer stage advances.
Circulating Tumor DNA Fragments Can Be Used to Assess a Patient's Response to Cancer Treatment
Research in 24 patients with colon and rectal (large bowel) cancer observed that tumors initially shrank in response to chemotherapy but subsequently began growing. Analyses of tumor DNA fragments before and after treatment identified new mutations causing cells to acquire drug resistance. In other words, somatic mutations acquired by these tumor cells caused the drugs to stop working.
Another point emphasized by researchers is that these tumor DNA fragments can be detected at all stages of cancer. Measuring tumor fragments in the blood could therefore allow predictions about cancer stage and a patient's survival.
Detecting Circulating Tumor Cells and Tumor-Derived Fragments Such as Tumor DNA Could Predict the Likelihood of Cancer Recurrence
Cancer cells leave residues below detectable levels even after treatment. According to research published in Science Translation Medicine in 2015, analyzing tumor DNA fragments in blood can identify whether early-stage breast cancer will recur (relapse) after treatment up to 8 months in advance. Our article on this subject can be accessed here .
Another study involved patients with large B-cell lymphoma. Research published in The Lancet Oncology in 2015 indicated that measuring tumor DNA fragments in blood can detect recurrence (relapse) much earlier than other imaging systems, even while the tumor is still microscopic. Researchers successfully identified cancer recurrence by analyzing tumor DNA fragments 3.4 months in advance. This paved the way for a blood test to spare patients procedures that impose financial and health burdens.
In conclusion, circulating tumor DNA fragments are an important marker that can be used effectively at every cancer stage. Tests soon to enter clinical use following recent studies will offer considerable convenience in cancer prevention and treatment.
Sources
2) Roschewski M, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncology. April 2, 2015.
3) Isaac Garcia-Murillaset. Al, Mutation Tracking In Circulating Tumor Dna Predicts Relapse In Early Breast Cancer, Science Translational Medicine,26 Aug 2015.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.